Systemic immunity in patients with recurrent vulvovaginal candidiasis;Systémová imunita u pacientek s rekurentní vulvovaginální kandidózou

Ceska Gynekologie

Volumn 70, Issue 6, 2005, Pages 453-459

  Jílek, Petr ^a,c   Spacek J ^a   Buchta, V ^a,b   Kucera Z ^a   Drahosova M ^a   Forstl M ^b   Andrys C ^a  

^a Farmaceutická Fakulta UK ^*  (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cell immunity; Humoral immunity; Recurrent vulvovaginal candidiasis

Indexed keywords

C REACTIVE PROTEIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; VAGINA CANDIDIASIS; VULVITIS;

ADOLESCENT; ADULT; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; MIDDLE AGED; RECURRENCE;

EID: 33144461924     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Buchta, V., Špaček, J. Mikrobiologické nálezy u pacientek s rekurentní vulvovaginální kandidózou ve Fakultní nemocnici Hradec Králové v letech 1995-2002. Čes. Gynek., 2004, 69, s. 7-15.
2. Cutler, J. E. The Candida albicans phosphomannan komplex in Candida-host interactions. Res. Immunol., 1998, 149, p. 299-308.
3. Fidel, P. L., Sobel, J. D. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev., 1996, 9, p. 335-348.
4. Fidel, P. L. Jr. Immunity in vaginal candidiasis. Curr. Opin. Infect. Dis. 2005, 18, p. 107-111.
5. Fidel, P. L., Jr. Lynch, M. E., Redondo-Lopez, V., et al. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC). J. Infect. Dis., 1993, 168, p. 1458-1465.
6. Fong, I. W., McCleary, P., Read, S. Cellular immunity in patients with recurrent or refractory vulvovaginal moniliasis. Am. J. Obstet. Gynecol., 1992, 166, p. 887-890.
7. Jilma, B., Dirnberger, E., Loscher, I., et al. Menstrual cycle-associated changes in blood levels of interleukin- Alpha 1 acid glykoprotein, and C-reactive protein. J. Lab. Clin. Med., 1997, 130, p. 69-75.
8. Kaminishi, H., Miyaguchi, H., Tamaki, T., et al. Degradation of humoral host defense by Candida albicans proteinase. Infect. Immun., 1995, 63, p. 984-988.
9. Kozel, T. R., Weinhold, L. C., Lupan, D. M. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun., 1996, 64, p. 3360-3368.
10. Kunzelmann, V., Tietz, H. J., Rossner, D., et al. Prerequisites for effective therapy of chronic recurrent vaginal candidiasis. Mycoses, 1996, 39, (Suppl. 1), p. 65-72.
11. Levitz, S. M. Overview of host defenses in fungal infections. CHn. Infect. Dis., 14, (Suppl. 1), 1992, p. 37-42.
12. Li, S. P., Lee, S., Domer, J. Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A. Infect. Immun., 1998, 66, p. 1392-1399.
13. Moraes, P. S., de Lima-Goiaba, S., Taketomi, E. A. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. J. Investig. Allergol. Clin-Immunol. 2000, 10, p. 305-309.
14. Murphy, J. W. Cell-Mediated Imunity and Medically Related Fungi. In: Effects of Microbes on the Immune System, Cunningham M. W., Fujinami R. S. (eds.). Lippincott Williams & Wilkins, Philadelphia, 2000. p. 593-621.
15. Parr, M. B., Parr, E. L. Mucosal immunity in the female and male reproductive tracts. In: Ogra P. L., Mestecky J., Lamm M. F., Strober W., McGhee J. R., Bienenstock J. (eds.). Handbook of mucosal immunity. 1st ed. San Diego: Academic Press, 1994, p. 677-689.
16. Pellis, V., de Seta, F., Crovella, S. et al. Mannose binding lectin and C3 act as recognition molecules for infectious agents in the vagina. Clin. Exp. Immunol. 2005, 139, p. 120-126.
17. Regulez, et al. Detection of anti-Candida albicans IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis. Gynecol. Obstet. Invest., 1994, 37, p. 110-114.
18. Ringdahl, E. N. Treatment of recurrent vulvovaginal candidiasis. Am. Fam. Physician, 2000, 61, p. 3306-3317.
19. Rodrigues, A. G., Mardh, P. A., Pina-Vaz, C., et al. Is the lack of concurence of bacterial vaginosis and vaginal candidosis explained by the presence of bacterial amines? Am. J. Obstet. Gynecol., 1999, 181, p. 367-370.
20. Romero-Piffiquer, M. D., Vucovich, P. R., Piera, C. M. Secretory IgA and secretory component in women affected by recidivant vaginal candidiasis. Mycopathologia, 1985, 91, p. 165-170.
21. Sobel, J. D. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann. N. Y. Acad. Sci., 1988, 544, p. 547-557.
22. Syversson, R. A., Buckley, H., Gibian, J., et al. Cellular and humoral immune status in women with chronic Candida vaginitis. Am. J. Obstet. Gynecol. 1979, 134, s. 624-627.
23. Špaček, J., Buchta, V. Itraconazole in the treatment of acute and recurrent vaginal candidosis: Comparison of a 1-day and 3-day regimen. Mycoses, 2005, 48, p. 165-171.
24. Špaček J., Buchta, V., Jílek, P., Förstl, M. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis, Submitted to press.
25. Špaček J., Buchta, V., Veselský, Z., Kalousek, I. Interakce kvasinek s hostitelem ve vztahu k urogenitálnímu traktu, vulvovaginální kandidóza, urologické aspekty mykotických onemocnění. Čes. Gynek 2003, 68, s. 432-439.
26. Špaček J., Jílek, P., Buchta, V., et al. Protihoubová imunita a její mechanismy ve vztahu k vulvovaginální kandidóze. Čes. Gynek., 2004, 69, s. 133-140.
27. Špaček, J., Jílek, P., Buchta, V., Jarošová, R. Současné názory na etiopatogenezi rekurentní vulvovaginálni kandidózy. Čes. Gynek., 1999, 64, s. 114-117.
28. Waldman, R. H., Cruz, J. M., Rowe, D. S. Immunoglobulin levels and antibody to Candida albicans in human cervicovaginal secretions. Clin. Exp. Immunol., 1972, 10, p. 227-234.
29. Wang, Y., Li, S. P., Moser, S. A., et al. Cytokine involvement in immunomodulatory activity affected by mannan. Infect. Immun., 1998, 66, p. 1384-1391.
30. Wira, C. R., Richardson, J., Prabhala, R. Endocrine regulation of mucosal immunity: effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract. In: Ogra P. L., Mestecky J., Lamm M. E., Strober W., McGhee J. R., Bienenstock J. (eds.) Handbook of mucosal immunity. 1st ed. San Diego, Academic Press, 1994, p. 705-718.
31. Wira, C. R., Stern, J. E. Endocrine regulation of the mucosal immune system in the female reproductive tract. Control of IgA. IgG, and secretory component during the reproductive cycle, at implantation, and throughout pregnancy. In: Pasqualini J. R. and Scholler R. (eds.), Hormones and fetal pathophysiology. 1992. Marcel Dekker, Inc., New York. p. 343-367.
32. Witkin, S. S., Jeremias, J., Ledger, W. J. A localized vaginal allergic response in women with recurrent vaginitis. J. Allergy Clin. Immunol., 1988, 81, p. 412-416.
33. Witkin, S. S., Jeremias, J., Ledger, W. J. Vaginal eosinophils and IgE to Candida albicans in women with recurrent vaginitis. J. Med. Vet. Mycol., 1989, 27, p. 57-58.
34. Wormley, F. L. Jr., Steele, C., Wozniak, K. et al. Resistance of T-cell receptor deltachain-deficient mice to experimental Candida albicans vaginitis. Infect. Immun. 2001, 69, p. 7162-7164.
35. Yamamura, M., Valdimarsson, H. Participation of C3 in intracellular killing of Candida albicans. Scand. J. Immunol., 1977, 6, p. 591-594.
36. Zdolsek, B., Hellberg, D., Fröman, G., et al. Vaginal microbiological flora and sexually transmitted diseases in women with recurrent vulvovaginal candidiasis. Infection, 1995, 23, p. 81-84.